An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.
VERDICT
The label
Accumulation
read at $40.52
Guardian Pharmacy Services, Inc. holds its Accumulation at $40.52.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 1 days
Price
$40.52
Valuation
48.24 trailing · 29.83 forward price to earnings
Values screen
PASS· score 70.0
Beta
N/A
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$40.52
48.24 P/E · 29.83 fwd
Our fair value
$38.44
5% premium
Analyst target (avg)
$47.00
+16% to current
Target low $43.00Analyst target rangeTarget high $50.00
▲ current $40.52 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$40.52
you are here
Conservative
$38.44
-5%
Analyst avg
$47.00
+16%
Our fair value
$38.44
-5%
Analyst high
$50.00
+23%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
2.20%
Profit margin
3.65%
Debt to equity
17.72
Analyst consensus
None · 6 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Care home pharmacies trade above fair value
Every pill dispensed inside a US nursing home moves through specialised pharmacy networks that keep residents medicated on time. Guardian Pharmacy Services runs that operation, supplying tech-enabled dispensing and clinical support to long-term care facilities across the country.
Revenue is expanding at just 2% while the forward multiple sits at 29.8 times and margins remain stuck at 4%. The shares trade at 40.52 against a fair value of 38.44, so there is no margin of safety and the opportunity rating stays at none despite the clean ethical screen.
Return on equity reaches 27%, yet unknown competitive strength and thin growth leave the business exposed to reimbursement cuts and regulatory shifts in healthcare. Analysts see a median target of 47, but that does not change the lack of value on offer today.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
GRDN trades on the NYSE. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. Entered 2026-07-31 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-31Accumulation$40.52-6.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
2026-07-18Accumulation$43.09+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
2026-07-03Accumulation$43.09+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$43.09Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$35.65
+17.6%
·
$1,176
+17.6%
2 months
$39.15
+7.1%
·
$1,071
+7.1%
3 months
$33.27
+26.1%
·
$1,261
+26.1%
6 months
$31.17
+34.6%
·
$1,346
+34.6%
1 year
$20.63
+103.3%
·
$2,033
+103.3%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever GRDN does next, these words stay.
Guardian Pharmacy Services, Inc. · GRDN · Accumulation · $40.52
Recorded 2026-07-19 · before the outcome · scored mechanically